A
Overview
ARC-One Solutions develops and implements a BECS platform to manage the U.S. blood supply. It is the software manufacturer for an FDA 510(k) cleared medical device and maintains the legacy RSA system in parallel during transition. It operates as a specialized technology provider created by and for leading blood centers, focusing on safety, regulatory compliance, and large-scale workflow across the sector. Its goal is to deliver a scalable, compliant software foundation that supports national blood supply management and data-driven decision-making for safe product delivery.
Work here?Claim your company
Simplify's take
What believers are saying
- FDA BK200512 clearance remains active, preserving regulatory credibility for ARC-One's software stack.
- The 2026 website says the platform supports over 50% of U.S. blood supply needs.
- Current positioning emphasizes compliance and operational standardization, attractive in heavily regulated healthcare software.
What critics are saying
- ARC-One depends on two parent blood centers, limiting customer diversity and bargaining power.
- No public deployment milestones since 2020 suggest a slow, capital-intensive replacement cycle.
- If Red Cross or OneBlood shifts vendors, ARC-One loses its entire economic base.
What makes ARC-One Solutions unique
- ARC-One Solutions owns FDA-cleared BECS IP built with American Red Cross and OneBlood.
- Its RSA platform already serves regulated blood workflows across collections, manufacturing, labeling, and distribution.
- The company targets 56 states and territories, with software built for national blood-network scale.
Help us improve and share your feedback! Did you find this helpful?